Pharmacology of Selumetinib for treatment of Neurofibromatosis-1 (New Drug 2020)
2 Views
administrator
07/02/23
Pharmacology of Selumetinib for treatment of Neurofibromatosis-1 (New Drug 2020)
MOA – MEK 1/2 or Mitogen Activated Protein Kinase 1/2 inhibitor
Use: Neurofibromatosis-1 which is symptomatic/inoperable
Effect: Selumetinib decreases size and number of neurofibromas.
Route – Oral
Dose – 25 mg/m2 on empty stomach
Side-effects:
GIT – N/V, Diarrhoea
Rhabdomyolysis
Ocular toxicity
Cardiomyopathy
-
Category
Show more
Facebook Comments
No comments found